EU blocks $7.1bn takeover of cancer detection company

Illumina bid would have “stifled innovation” | EU said Illumina was the "unrivalled supplier” of next-generation sequencing systems for genetic and genomic analysis.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia

BGI wins $333m in DNA patent suit with Illumina

9 May 2022 Illumina has been ordered to pay more than $333 million to Chinese sequencing company MGI—a subsidiary of BGI Group formally known as Complete Genomics—following a jury ruling that Illumina infringed two of its DNA-sequencing patents.

Big Pharma

Illumina prevails against BGI at English High Court

21 January 2021 Illumina has secured a victory in its patent dispute with Chinese genome sequencing company BGI at the English High Court, which ruled that four of its patents had been infringed.

Big Pharma

Exelixis takes Cipla to court over generic cancer drug

21 March 2023 Cipla claims Cabometyx patents are invalid | Exelixis wants generic blocked until at least 2030.

More on this story

Asia

BGI wins $333m in DNA patent suit with Illumina

Big Pharma

Illumina prevails against BGI at English High Court

21 January 2021 Illumina has secured a victory in its patent dispute with Chinese genome sequencing company BGI at the English High Court, which ruled that four of its patents had been infringed.

Big Pharma

Exelixis takes Cipla to court over generic cancer drug

21 March 2023 Cipla claims Cabometyx patents are invalid | Exelixis wants generic blocked until at least 2030.

More on this story

Asia

BGI wins $333m in DNA patent suit with Illumina

Big Pharma

Illumina prevails against BGI at English High Court

21 January 2021 Illumina has secured a victory in its patent dispute with Chinese genome sequencing company BGI at the English High Court, which ruled that four of its patents had been infringed.

Big Pharma

Exelixis takes Cipla to court over generic cancer drug

21 March 2023 Cipla claims Cabometyx patents are invalid | Exelixis wants generic blocked until at least 2030.